Lergonix (Bilastine)

Bilastine works by selectively blocking peripheral H1 histamine receptors on mast cells, basophils and other tissues. By preventing histamine from binding, it stops the cascade that leads to increased vascular permeability, smooth‑muscle contraction and nerve stimulation, thereby reducing typical allergy symptoms.

The appropriate dose of Lergonix is determined by a qualified healthcare professional based on the patient’s age, condition and other factors. Prescribers follow local labeling and clinical guidelines to select the correct tablet strength and dosing schedule.

Safety data for bilastine in pregnancy and lactation are limited. It is classified as pregnancy category unknown, and the risk‑benefit ratio should be evaluated by a physician. Breastfeeding mothers should discuss potential exposure with their healthcare provider before use.

To request Lergonix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with first‑generation antihistamines, bilastine offers similar efficacy for allergic symptoms but with a lower risk of sedation and anticholinergic effects. Within the second‑generation class, its potency and selectivity are comparable to cetirizine and fexofenadine, while maintaining a favorable safety profile.

Lergonix tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and keep out of reach of children.

Lergonix is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional. Administration can be with or without food, as advised by the prescriber.

Although rare, serious adverse reactions may include anaphylaxis, Stevens‑Johnson syndrome and angioedema. Patients should seek immediate medical attention if they experience symptoms such as swelling of the face or throat, severe rash, or difficulty breathing after taking the medication.

Lergonix is contraindicated in individuals with known hypersensitivity to bilastine or any tablet excipients. Caution is also advised for patients with severe renal impairment, pregnant or nursing women, and those taking strong CYP3A4 inhibitors, unless a physician determines that benefits outweigh the risks.